This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A phase II, open-label, single-arm, non-randomized...
Clinical trial

A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer

Read time: 1 mins
Last updated:19th Apr 2012
To assess the antitumor activity of TKI258, as measured by an 18-week progression free survival (PFS) rate, in patients with pre-treated endometrial cancer, with or without FGFR2 mutation.
Category Value
Study start date 2012-04-19

View full details